humanitarian
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised
Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision…
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
12 reports · 2 sources
EMA What Is NewHuman medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Deferasirox Mylan, deferasirox, Date of authorisation: 26/09/2019, Revision: 14, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Deferasirox Mylan, deferasirox, Date of authorisation: 26/09/2019, Revision: 14, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Date of authorisation: 19/04/2018, Revision: 13, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Fovlussea, ranibizumab, Ophthalmologicals, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion2 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources